Last reviewed · How we verify
Oral Naltrexone (O-NTX)
Oral naltrexone is an opioid receptor antagonist that blocks opioid signaling in the central and peripheral nervous system.
Oral naltrexone is an opioid antagonist that blocks opioid receptors in the central and peripheral nervous system. Used for Opioid use disorder, Alcohol use disorder.
At a glance
| Generic name | Oral Naltrexone (O-NTX) |
|---|---|
| Also known as | Revia |
| Sponsor | NYU Langone Health |
| Drug class | Opioid antagonist |
| Target | Opioid receptors (mu, delta, kappa) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Addiction Medicine |
| Phase | FDA-approved |
Mechanism of action
Naltrexone competitively binds to opioid receptors (mu, delta, and kappa), preventing endogenous opioids and exogenous opioid drugs from activating these receptors. This mechanism is used clinically to reduce cravings and block the rewarding effects of opioids in opioid use disorder, and at lower doses to modulate immune and pain pathways in other conditions.
Approved indications
- Opioid use disorder (maintenance treatment)
- Alcohol use disorder
Common side effects
- Nausea
- Headache
- Anxiety
- Insomnia
- Abdominal pain
- Joint/muscle pain
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oral Naltrexone (O-NTX) CI brief — competitive landscape report
- Oral Naltrexone (O-NTX) updates RSS · CI watch RSS
- NYU Langone Health portfolio CI